Orsière T G, Chauvet M M, Dell'Amico M H, Bourdeaux M J
Equipe Protéines Membranaires (GRIPP), URA-CNRS 1924, UFR de Pharmacie, Marseille, France.
Eur J Pharmacol. 1995 Nov 30;291(3):237-43. doi: 10.1016/0922-4106(95)90063-2.
As little work has dealt with the antihyperglycemic property of benfluorex at the hepatocyte level, we studied the effects of its main metabolites, S422 and S1475, on membrane fluidity and on insulin binding, internalization and action in healthy rat hepatocytes. Both metabolites were effective fluidizing agents. Neither one affected insulin binding. Only S422 favored the bound insulin-receptor internalization process. The metabolites produced no change in basal alpha-aminoisobutyric acid uptake. Only S422 promoted the insulin-stimulated alpha-aminoisobutyric acid uptake in a dose-dependent way. Therefore, our study demonstrated that: (i) the effects of S422 on insulin-related processes in isolated hepatocytes were direct, specific and not due to any membrane fluidizing mechanism; (ii) S422 improved hepatocyte response to insulin at a post-binding level. These results in vitro give an additional explanation, at the cellular level, of the benefit of benfluorex treatment for non insulin-dependent diabetes patients.
由于很少有研究涉及苯氟雷司在肝细胞水平上的降血糖特性,我们研究了其主要代谢产物S422和S1475对健康大鼠肝细胞的膜流动性、胰岛素结合、内化及作用的影响。两种代谢产物都是有效的膜流动性增强剂。它们均不影响胰岛素结合。只有S422有利于结合的胰岛素-受体内化过程。这些代谢产物对基础α-氨基异丁酸摄取没有影响。只有S422以剂量依赖的方式促进胰岛素刺激的α-氨基异丁酸摄取。因此,我们的研究表明:(i)S422对分离的肝细胞中胰岛素相关过程的影响是直接、特异的,并非由于任何膜流动性机制;(ii)S422在结合后水平改善了肝细胞对胰岛素的反应。这些体外研究结果在细胞水平上为苯氟雷司治疗非胰岛素依赖型糖尿病患者的益处提供了额外的解释。